Literature DB >> 16111884

Vitamin D receptor (VDR) ablation alters carcinogen-induced tumorigenesis in mammary gland, epidermis and lymphoid tissues.

Glendon M Zinser1, Mark Suckow, JoEllen Welsh.   

Abstract

The Vitamin D receptor (VDR) and its ligand, 1,25(OH)(2)D(3), regulate cell proliferation, differentiation and apoptosis in vitro, yet the physiological significance of this regulation is unclear. In these studies, we used VDR knockout (VDRKO) mice to examine the impact of VDR on chemical carcinogen-induced tumorigenesis in vivo. Wild type (WT) and VDRKO littermates were fed a high calcium diet to prevent disturbances in calcium homeostasis and were gavaged with dimethylbenzanthracence (DMBA) using a protocol designed to induce mammary tumors. Compared to WT littermates, VDRKO mice exhibited an increased incidence of mammary gland hyperplasia and a higher percentage of hormone independent tumors with squamous differentiation. VDR ablation also significantly enhanced tumor development in epidermis and lymphoid tissues, but did not affect tumor development in ovary, uterus, lung or liver. These data indicate that VDR ablation alters susceptibility to DMBA-induced carcinogenesis in a tissue specific fashion, and provide support that optimal VDR signaling may act to suppress tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16111884     DOI: 10.1016/j.jsbmb.2005.06.024

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  50 in total

Review 1.  Vitamin D and cancer: a review of molecular mechanisms.

Authors:  James C Fleet; Marsha DeSmet; Robert Johnson; Yan Li
Journal:  Biochem J       Date:  2012-01-01       Impact factor: 3.857

2.  Dietary vitamin D and vitamin D receptor level modulate epithelial cell proliferation and apoptosis in the prostate.

Authors:  Pavlo L Kovalenko; Zhentao Zhang; Jun-Ge Yu; Yan Li; Steven K Clinton; James C Fleet
Journal:  Cancer Prev Res (Phila)       Date:  2011-08-11

3.  Pilot study on the bioactivity of vitamin d in the skin after oral supplementation.

Authors:  Clara Curiel-Lewandrowski; Jean Y Tang; Janine G Einspahr; Yira Bermudez; Chiu Hsieh Hsu; Melika Rezaee; Alex H Lee; Joseph Tangrea; Howard L Parnes; David S Alberts; H-H Sherry Chow
Journal:  Cancer Prev Res (Phila)       Date:  2015-04-02

4.  The potential role of vitamin D in the progression of benign and malignant melanocytic neoplasms.

Authors:  Joel Pinczewski; Andrzej Slominski
Journal:  Exp Dermatol       Date:  2010-10       Impact factor: 3.960

Review 5.  Vitamin D and differentiation in cancer.

Authors:  Elzbieta Gocek; George P Studzinski
Journal:  Crit Rev Clin Lab Sci       Date:  2009       Impact factor: 6.250

Review 6.  Minireview: Vitamin D: is there a role in extraskeletal health?

Authors:  Sylvia Christakos; Hector F DeLuca
Journal:  Endocrinology       Date:  2011-06-14       Impact factor: 4.736

Review 7.  Vitamin D in cutaneous carcinogenesis: part II.

Authors:  Jean Y Tang; Teresa Fu; Christopher Lau; Dennis H Oh; Daniel D Bikle; Maryam M Asgari
Journal:  J Am Acad Dermatol       Date:  2012-11       Impact factor: 11.527

8.  CCAAT enhancer-binding protein alpha is a molecular target of 1,25-dihydroxyvitamin D3 in MCF-7 breast cancer cells.

Authors:  Puneet Dhawan; Robert Wieder; Robert Weider; Sylvia Christakos
Journal:  J Biol Chem       Date:  2008-12-03       Impact factor: 5.157

9.  Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions.

Authors:  Nair Lopes; Bárbara Sousa; Diana Martins; Madalena Gomes; Daniella Vieira; Luiz A Veronese; Fernanda Milanezi; Joana Paredes; José L Costa; Fernando Schmitt
Journal:  BMC Cancer       Date:  2010-09-11       Impact factor: 4.430

Review 10.  The yin and yang of vitamin D receptor (VDR) signaling in neoplastic progression: operational networks and tissue-specific growth control.

Authors:  F C Campbell; Haibo Xu; M El-Tanani; P Crowe; V Bingham
Journal:  Biochem Pharmacol       Date:  2009-09-06       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.